January 19th 2023
Tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF), antiretroviral drugs used to treat HIV and hepatitis B, may be simultaneously depleting the energy of immune cells.
If Priced Right, Long-Acting Injectable Cabotegravir Could Reduce Spread of HIV
December 13th 2022For this to be a viable HIV reduction strategy, scale-up demand creation should be coordinated between all partners, the study authors said, and should be fast enough to build momentum and yield the expected results.
Read More
HIV and Aging in the Era of Antiretroviral Therapy: Considerations in Clinical Care
October 28th 2022With the population of adults with HIV growing older, incorporating age-based screenings, comprehensive assessments, and morbidity management into routine HIV care is essential in improving health outcomes and quality of life.
Read More
Gender-Affirming Care in Persons Living With HIV
September 19th 2022Gender-affirming hormone therapy (GAHT) therapy consists of administration of exogenous hormones and suppression of endogenous hormone production, with the goal of obtaining characteristics more congruent with an individual’s gender identity. Here is a review of these therapies and consideration for PrEP and the risks associated with HIV in this diverse population.
Read More
Incidence of STIs Stabilized Among Gay and Bisexual Men Using HIV PrEP
August 9th 2022After widespread implementation of HIV pre-exposure prophylaxis (PrEP) among gay and bisexual men in Australia, population-level incidence of chlamydia and gonorrhea stabilized, allaying fears that PrEP would lead to a rise in STIs, a recent study found.
Read More